Ranitidine and risk of bladder and kidney cancer: A population-based cohort study
Cancer Epidemiology, Biomarkers & Prevention Nov 22, 2021
Nørgaard M, Andersen IT, Heide-Jørgensen U, et al. - Use of ranitidine was not associated with a substantial increase in bladder or kidney cancer occurrence.
Withdrawal of ranitidine in 2019 was because of high levels of N-nitrosodimethylamine, a probable human carcinogen.
This is a Danish nationwide cohort study including 31,393 initiators (adults 18 years or older) of ranitidine, 65,384 initiating other H2-blockers (H2-receptor antagonists), and 509,849 initiating proton pump inhibitors (PPI), to clarify risk of bladder and kidney cancer in ranitidine users.
Experts employed propensity scores for ranitidine use to calculate stabilized inverse probability of treatment (sIPT) weights as well as applied Cox regression to estimate crude and weighted HRs.
Relative to other H2-blockers, the crude HR for bladder cancer was estimated to be 1.33, but sIPT weighting attenuated this to 1.11.
The estimated weighted HR was 1.24 (95% CI: 1.04–1.48) vs PPI initiators.
The weighted HR for kidney cancer was 0.89 (95% CI: 0.72–1.10) vs users of H2-blockers and 0.87 (95% CI: 0.67–1.13) vs users of PPI.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries